Lexaria Bioscience annual ebitda
2015
2016
2021
2022
2023
2024
2025
Lexaria Bioscience EBITDA Growth & History (LEXX)
Lexaria Bioscience's calculated EBITDA was −$11.8M for fiscal 2025.
View full Lexaria Bioscience company overviewLexaria Bioscience annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-08-31 | −$11.8M | −$6.1M | — |
| 2024 | 2024-08-31 | −$5.7M | $677,943 | — |
| 2023 | 2023-08-31 | −$6.4M | $127,696 | — |
| 2022 | 2022-08-31 | −$6.5M | −$941,187 | — |
| 2021 | 2021-08-31 | −$5.6M | — | — |
| 2016 | 2016-08-31 | −$1.3M | $706,640 | — |
| 2015 | 2015-08-31 | −$2.0M | — | — |
Lexaria Bioscience quarterly ebitda
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q1.18
Q2.18
Q3.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-05-31 | −$2.0M | $1.7M | — |
| Q2 2026 | 2026-02-28 | −$1.4M | $1.3M | — |
| Q1 2026 | 2025-11-30 | −$1.6M | $1.1M | — |
| Q4 2025 | 2025-08-31 | −$2.7M | −$456,188 | — |
| Q3 2025 | 2025-05-31 | −$3.7M | −$2.0M | — |
| Q2 2025 | 2025-02-28 | −$2.7M | −$2.1M | — |
| Q1 2025 | 2024-11-30 | −$2.7M | −$1.6M | — |
| Q4 2024 | 2024-08-31 | −$2.2M | −$1.2M | — |
| Q3 2024 | 2024-05-31 | −$1.7M | $648,010 | — |
| Q2 2024 | 2024-02-29 | −$652,074 | $646,822 | — |
| Q1 2024 | 2023-11-30 | −$1.1M | $560,325 | — |
| Q4 2023 | 2023-08-31 | −$1.0M | — | — |
| Q3 2023 | 2023-05-31 | −$2.4M | $18,590 | — |
| Q2 2023 | 2023-02-28 | −$1.3M | — | — |
| Q1 2023 | 2022-11-30 | −$1.7M | — | — |
| Q3 2022 | 2022-05-31 | −$2.4M | $140,742 | — |
| Q3 2021 | 2021-05-31 | −$2.5M | — | — |
| Q2 2018 | 2018-02-28 | −$1.4M | −$913,306 | — |
| Q1 2018 | 2017-11-30 | −$576,650 | −$176,469 | — |
| Q2 2017 | 2017-02-28 | −$464,610 | −$190,207 | — |
| Q1 2017 | 2016-11-30 | −$400,181 | $11,406 | — |
| Q4 2016 | 2016-08-31 | −$326,903 | — | — |
| Q3 2016 | 2016-05-31 | −$263,737 | $247,271 | — |
| Q2 2016 | 2016-02-29 | −$274,403 | — | — |
| Q1 2016 | 2015-11-30 | −$411,587 | — | — |
| Q3 2015 | 2015-05-31 | −$511,008 | — | — |
Lexaria Bioscience ebitda trends
Between the periods ended 2015-08-31 and 2025-08-31, Lexaria Bioscience's ebitda decreased from −$2.0M to −$11.8M, a change of −$9.8M. The latest reported quarter, Q3 2026, shows −$2.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lexaria Bioscience source filings ↗